BACKGROUND AND QUESTION ASKED: Clinical guidelines recommend chemotherapy for patients with stage IV non-small-cell lung cancer (NSCLC) who have good to fair performance status, but not poor performance status. However, there is growing concern about use of chemotherapy in patients who are less likely to benefit. What are the rates of oncologists' selfreported likelihood to recommend chemotherapy for patients with stage IV NSCLC by performance status and symptoms, and how do recommendations vary by physician and practice characteristics?SUMMARY ANSWER: Nearly all oncologists reported that they would recommend chemotherapy for patients with good performance status, and approximately half reported they would recommend it for patients with poor performance status. Oncologists in multispecialty medical groups, hospital-based practices, and cancer center-based practices were less likely to make such recommendations.
WHAT WE DID:We surveyed medical oncologists involved in the care of a population-based cohort of patients with lung cancer from the Cancer Care Outcomes Research and Surveillance study. Oncologists were queried about their likelihood to recommend chemotherapy for patients with stage IV lung cancer with varying performance status (Eastern Cooperative Oncology Group performance status 0 [good] v 3 [poor]) and presence or absence of tumor-related pain. Repeated measures logistic regression was used to estimate the independent associations of patients' performance status and symptoms, and oncologists' demographic and practice characteristics with chemotherapy recommendations.WHAT WE FOUND: Nearly all oncologists (adjusted rates, 97% to 99%) reported that they would recommend chemotherapy for patients with good performance status, and approximately half (adjusted rate, 38% to 53%) reported they would recommend chemotherapy for patients with poor performance status (P , .001; Fig). Compared with patient factors, physician and practice characteristics were less strongly associated with chemotherapy recommendations in adjusted analyses.
BIAS, CONFOUNDING FACTORS, AND DRAWBACKS:Findings are based on self-reported recommendations, not actual behavior. It is uncertain whether oncologists would have responded differently if performance status had been specified as being secondary to the cancer, its symptoms, or other comorbidities. Actual treatment recommendations would likely be influenced by patient preferences, which were not provided as part of the clinical scenarios. Finally, oncologists in this study were surveyed in 2006 to 2008; responses might differ among oncologists surveyed more recently.
REAL-LIFE IMPLICATIONS:Approximately half of all patients with NSCLC are diagnosed with stage IV disease. A substantial proportion of these present with poor performance status. Evidence indicates that chemotherapy can prolong survival by a median of 8 to 12 weeks in patients with stage IV NSCLC and good performance status compared with best supportive care alone, and-for much of the past decade-guidelines have recommend...